Skip to main content

Table 1 Demographic comparison between training and validation cohorts

From: A clinical-radiomics nomogram for the preoperative prediction of lymph node metastasis in colorectal cancer

CharacteristicTraining cohortValidation cohortP
Age, mean SD58.86 ± 12.3859.12 ± 11.530.48
Tumor size, mean SD4.48 ± 1.914.53 ± 1.820.25
Sex (%)0.62
 Male258.0 (60.71%)167.0 (39.29%) 
 Female200.0 (58.65%)141.0 (41.35%) 
M stage (%)0.56
 M0399.0 (60.27%)263.0 (39.73%) 
 M159.0 (56.73%)45.0 (43.27%) 
CA19-9 (%)0.94
 0–27 U/mL362.0 (59.64%)245.0 (40.36%) 
 ≥27 U/mL96.0 (60.38%)63.0 (39.62%) 
CEA (%)0.08
 0–5 ng/mL298.0 (62.34%)180.0 (37.66%) 
 ≥ 5 ng/mL160.0 (55.56%)128.0 (44.44%) 
Location (%)0.42
 Right208.0 (61.54%)130.0 (38.46%) 
 Left250.0 (58.41%)178.0 (41.59%) 
Grade (%)0.63
 High26.0 (5.68%)21.0 (6.82%) 
 Middle301.0 (65.72%)207.0 (67.21%) 
 Low131.0 (28.60%)80.0 (25.97%) 
Histotype (%)0.93
 Adenocarcinoma379.0 (82.75%)258.0 (83.77%) 
 Mucinous histology74.0 (16.16%)47.0 (15.26%) 
 Signet ring cell differentiation5.0 (1.09%)3.0 (0.97%) 
  1. Chi-Square or Fisher Exact tests, as appropriate, were used to compare the differences in categorical variables (gender, M stage, CA19-9 level, CEA level, location, grade, histotype), while a two-sample t-test was used to compare the differences in age and tumor size. Laboratory analysis of CEA and CA 19-9 were done via routine blood tests within 1 week before surgery. The threshold value for CEA level was ≤ 5 ng/mL and > 5 ng/mL and the threshold value for CA 19-9 level was ≤ 27 U/mL and > 27 U/mL, according to the normal range used in clinics
  2. CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9